Ergün Parmaksız

Kartal Dr Lütfi Kırdar Şehir Hastanesi, İç Hastalıkları,Nefroloji Bölümü,iyi bir Fenerbahçeli,twettlerim tibbi tavsiye değildir.

[Ergün Parmaksız @Ergn26008141]

Genç meslektaşlarıma bir ömür başarılar dilerim.

[Boonyarit Cheunsuchon, MD @roboonya]

Glomerulonephritis in SLE does not always mean lupus nephritis. The authors used KM55 staining to differentiate IgAN from LN in 3 SLE patients.
https://t.co/7kLMkAe0U5

[Brian Rifkin, MD @brian_rifkin]

Do they work similar to HIF PHIs? #ERA26

[ERA - European Renal Association @ERAkidney]

3/ Take-home messages from the session! Important points:

🎯Only 18% of post-transplant patients have systemic findings of TMA!

🎯Histology was not predictive of the outcome in multivariate analysis.

🎯Does histology help to predict the cause of TMA? Not really!

#ERA26

[ERA - European Renal Association @ERAkidney]

2/ While prediction models help in MGRS, certain limitations remain—particularly regarding the management of non-biopsied patients. 📒 #ERA26

[Arunkumar @Arunkr_Dr]

#ERA26 #IgG4RelatedDisease by Dr Augusto Vaglio

🔹When thinking of #IgG4RD and the kidney, think beyond TIN.
🔹Renal involvement spans TIN, MN, and RPF, with distinct clinical phenotypes and presentations.
🔹Hypocomplementemia and elevated IgG4 provide valuable diagnostic clues

[Jasmine Sethi @JasmineNephro]

🥜Nutcracker Syndrome

https://t.co/3xX7KfrTuW

@CKJsocial

[Ergün Parmaksız @Ergn26008141]

@marcoasensio10 We are pleased with you, we're glad you're here

[Ergün Parmaksız @Ergn26008141]

@MatteoGuendouzi We are pleased with you, we're glad you're here

[ERA - European Renal Association @ERAkidney]

🧵 1/12
🩺 Diabetes management remains a cornerstone of care in the dialysis population. In this outstanding ✨#ERA e-seminar by the EUDIAL & Diabesity Working Groups, our experts dive into the clinical nuances of “finding the sweet spot” for patient outcomes.
@drkazancioglu🇹🇷, @maxtorreggiani🇫🇷; @valerieluyckx🇨🇭

Watch the full webinar 🔗 https://t.co/PpagVIjd2P
Missed the session? Not much time? Catch the highlights in this thread 👇👇👇

[ERA - European Renal Association @ERAkidney]

🧵 4/12📊 Glycaemic control & targets in dialysis
HbA1c remains the best analytical marker, BUT it underestimates true glucose exposure!
📚 DOPPS study suggests:
•Optimal HbA1c range = 7–8%; ⬇️ hypoglycaemia + ⬇️ long-term complications
•Targets are NOT one-size-fits-all: Must individualize!🎯
📚 KDIGO guidelines:
• No specific HbA1c target for HD patients
• Suggests individualised goals (≈6.5–8%) in CKD (Grade 1C)
• Novelty: CGM (continuous glucose monitoring) targets: Time in range >70% & Time below range <1%

Source: KDIGO 2022

[Ergün Parmaksız @Ergn26008141]

Sglt2i

[Dr sthanu subramanian @drsthanus]

Possible mechanisms underlying the cardioprotective effects of SGLT2is on HF.

https://t.co/8jiMks0uzc

[Dr sthanu subramanian @drsthanus]

Possible mechanisms underlying the cardioprotective effects of SGLT2is on HF.

https://t.co/8jiMks0uzc

[Ergün Parmaksız @Ergn26008141]

@tabiiresmi Mükemmel dizi olmuş,wmegi geçenlere tesekkürler,Artovalı Yahya yeni yeni kahramanımız.

[Ergün Parmaksız @Ergn26008141]

#onbeşliler Emegi geçen herkese teşekkürler,son zamanların en güzel basyapıtı.

[Ergün Parmaksız @Ergn26008141]

@vefasultantrt Teşekkürler,muhteşemdi.

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging Therapies ca. 2026 from @KidneyMed @JZRenalPath @IgAN_JBarratt @GlassockJ @DrRaymondHsu @Nephronpower @rahaai @SaynaNorouzi

📢 This paper is a very timely read for #NephMadness #Nephpearls

👉🆓 https://t.co/ATUOv7OAYQ

Nephmadness 👉 https://t.co/cqv1HK72v3

[Ergün Parmaksız @Ergn26008141]

@myparmaksiz @Meta Tebrikler kardeşim